CROWN trail updated 5 Years outcomes
Solomon BJ et al., Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study, J Clin Oncol. 2024 in press.
Editorial, JCO September 2024
Christine M. Lovly New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years. JCO 42, 3383-3386(2024).
DOI:10.1200/JCO.24.0114
